Literature DB >> 11812741

A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone.

Jon D Piganelli1, Sonia C Flores, Coral Cruz, Jeffrey Koepp, Ines Batinic-Haberle, James Crapo, Brian Day, Remy Kachadourian, Rebekah Young, Brenda Bradley, Kathryn Haskins.   

Abstract

We present here the first report of a metalloporphyrin-based antioxidant that can prevent or delay the onset of autoimmune diabetes. Type 1 diabetes is an autoimmune process whereby T-cells recognize pancreatic beta-cell antigens and initiate a leukocyte infiltrate that produces proinflammatory cytokines and reactive oxygen species (ROS), ultimately leading to beta-cell destruction. Because islet beta-cells have a reduced capacity to scavenge free radicals, they are very sensitive to ROS action. Metalloporphyrin-based superoxide dismutase (SOD) mimics scavenge ROS and protect cells from oxidative stress and apoptosis. To investigate the effect of SOD mimics and the role of oxidative stress in the development of autoimmune diabetes in vivo, we used a diabetogenic T-cell clone, BDC-2.5, to induce rapid onset of diabetes in young nonobese diabetic-severe combined immunodeficient mice (NOD.scid). Disease was significantly delayed or prevented altogether by treatment of recipient mice with an SOD mimic, AEOL-10113, before transfer of the BDC-2.5 clone. To investigate the mechanisms of protection, in vitro assays for T-cell proliferation and gamma-interferon (IFN-gamma) production were carried out using the T-cell clone BDC-2.5. We found that the SOD mimic significantly inhibited antigen-presenting cell-dependent T-cell proliferation and IFN-gamma production in vitro. In addition, pretreatment of lipopolysaccharide (LPS)-stimulated peritoneal macrophages with SOD mimic inhibited the LPS-dependent increase in TNF-alpha as well as the NADPH oxidase-dependent release of superoxide. Finally, this compound protected NIT-1 insulinoma cells from interleukin-1beta and alloxan cytotoxicity in vitro.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812741     DOI: 10.2337/diabetes.51.2.347

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  77 in total

1.  Changing the energy of an immune response.

Authors:  Meghan M Delmastro-Greenwood; Jon D Piganelli
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

2.  Endoscopic biopsy of islet transplants in the gastric submucosal space provides evidence of islet graft rejection in diabetic pigs.

Authors:  Takayuki Tanaka; Minoru Fujita; Rita Bottino; Jon D Piganelli; Kevin McGrath; Jiang Li; Whayoung Lee; Hayato Iwase; Martin Wijkstrom; Suzanne Bertera; Cassandra Long; Douglas Landsittel; Ken Haruma; David K C Cooper; Hidetaka Hara
Journal:  Islets       Date:  2016-02-08       Impact factor: 2.694

3.  Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease.

Authors:  Agnė Žiniauskaitė; Symantas Ragauskas; Anita K Ghosh; Rubina Thapa; Anne E Roessler; Peter Koulen; Giedrius Kalesnykas; Jenni J Hakkarainen; Simon Kaja
Journal:  Ocul Surf       Date:  2019-02-23       Impact factor: 5.033

4.  Spotlight on ethnomedicine: usability of Sutherlandia frutescens in the treatment of diabetes.

Authors:  Charles Sia
Journal:  Rev Diabet Stud       Date:  2004-11-10

5.  Inactivation of specific β cell transcription factors in type 2 diabetes.

Authors:  Shuangli Guo; Chunhua Dai; Min Guo; Brandon Taylor; Jamie S Harmon; Maike Sander; R Paul Robertson; Alvin C Powers; Roland Stein
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

Review 6.  Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities.

Authors:  Ines Batinic-Haberle; Ivan Spasojevic; Hubert M Tse; Artak Tovmasyan; Zrinka Rajic; Daret K St Clair; Zeljko Vujaskovic; Mark W Dewhirst; Jon D Piganelli
Journal:  Amino Acids       Date:  2010-05-16       Impact factor: 3.520

7.  Comprehensive pharmacokinetic studies and oral bioavailability of two Mn porphyrin-based SOD mimics, MnTE-2-PyP5+ and MnTnHex-2-PyP5+.

Authors:  Tin Weitner; Ivan Kos; Huaxin Sheng; Artak Tovmasyan; Julio S Reboucas; Ping Fan; David S Warner; Zeljko Vujaskovic; Ines Batinic-Haberle; Ivan Spasojevic
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

8.  Antioxidant treatment regulates the humoral immune response during acute viral infection.

Authors:  Katie E Crump; P Kent Langston; Sujana Rajkarnikar; Jason M Grayson
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  Impact of electrostatics in redox modulation of oxidative stress by Mn porphyrins: protection of SOD-deficient Escherichia coli via alternative mechanism where Mn porphyrin acts as a Mn carrier.

Authors:  Júlio S Rebouças; Gilson DeFreitas-Silva; Ivan Spasojević; Ynara M Idemori; Ludmil Benov; Ines Batinić-Haberle
Journal:  Free Radic Biol Med       Date:  2008-05-05       Impact factor: 7.376

10.  High lipophilicity of meta Mn(III) N-alkylpyridylporphyrin-based superoxide dismutase mimics compensates for their lower antioxidant potency and makes them as effective as ortho analogues in protecting superoxide dismutase-deficient Escherichia coli.

Authors:  Ivan Kos; Ludmil Benov; Ivan Spasojević; Júlio S Rebouças; Ines Batinić-Haberle
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.